BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 31182137)

  • 21. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.
    Jin S; Yang X; Li J; Yang W; Ma H; Zhang Z
    Mol Cancer; 2019 Mar; 18(1):38. PubMed ID: 30857539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The CCAAT box binding transcription factor, nuclear factor-Y (NF-Y) regulates transcription of human aldo-keto reductase 1C1 (AKR1C1) gene.
    Pallai R; Simpkins H; Chen J; Parekh HK
    Gene; 2010 Jul; 459(1-2):11-23. PubMed ID: 20338228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.
    Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B
    Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling.
    Cui B; Chen J; Luo M; Wang L; Chen H; Kang Y; Wang J; Zhou X; Feng Y; Zhang P
    Int J Oncol; 2020 Apr; 56(4):909-920. PubMed ID: 32319563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
    Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
    Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
    Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
    Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
    Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
    Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells.
    Vahabi M; Pulito C; Sacconi A; Donzelli S; D'Andrea M; Manciocco V; Pellini R; Paci P; Sanguineti G; Strigari L; Spriano G; Muti P; Pandolfi PP; Strano S; Safarian S; Ganci F; Blandino G
    J Exp Clin Cancer Res; 2019 Mar; 38(1):141. PubMed ID: 30925916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated Nrf2-antioxidant pathway activation.
    Noman ASM; Parag RR; Rashid MI; Islam S; Rahman MZ; Chowdhury AA; Sultana A; Jerin C; Siddiqua A; Rahman L; Nayeem J; Akther S; Baidya S; Shil RK; Rahman M; Shirin A; Mahmud R; Hossain SMI; Sumi SA; Chowdhury A; Basher SB; Hasan A; Bithy S; Aklima J; Chowdhury N; Hasan MN; Banu T; Chowdhury S; Hossain MM; Yeger H; Farhat WA; Islam SS
    Cell Death Dis; 2020 Aug; 11(8):663. PubMed ID: 32814771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The interaction of interleukin-8 and PTEN inactivation promotes the malignant progression of head and neck squamous cell carcinoma via the STAT3 pathway.
    Xu Q; Ma H; Chang H; Feng Z; Zhang C; Yang X
    Cell Death Dis; 2020 May; 11(5):405. PubMed ID: 32471980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
    Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
    Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53-independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells.
    Sharma K; Vu TT; Cook W; Naseri M; Zhan K; Nakajima W; Harada H
    Mol Oncol; 2018 Jun; 12(6):788-798. PubMed ID: 29352505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The
    Fukusumi T; Guo TW; Sakai A; Ando M; Ren S; Haft S; Liu C; Amornphimoltham P; Gutkind JS; Califano JA
    Clin Cancer Res; 2018 Feb; 24(3):619-633. PubMed ID: 29146722
    [No Abstract]   [Full Text] [Related]  

  • 34. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
    Zeng L; Nikolaev A; Xing C; Della Manna DL; Yang ES
    Mol Cancer Ther; 2020 Jun; 19(6):1279-1288. PubMed ID: 32371584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib.
    Lin C; Ren Z; Yang X; Yang R; Chen Y; Liu Z; Dai Z; Zhang Y; He Y; Zhang C; Wang X; Cao W; Ji T
    Cancer Lett; 2020 Mar; 472():81-96. PubMed ID: 31838083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC).
    Zhang F; Li Y; Zhang H; Huang E; Gao L; Luo W; Wei Q; Fan J; Song D; Liao J; Zou Y; Liu F; Liu J; Huang J; Guo D; Ma C; Hu X; Li L; Qu X; Chen L; Yu X; Zhang Z; Wu T; Luu HH; Haydon RC; Song J; He TC; Ji P
    Oncotarget; 2017 Feb; 8(8):12968-12982. PubMed ID: 28099902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells.
    Subramanian C; Kovatch KJ; Sim MW; Wang G; Prince ME; Carey TE; Davis R; Blagg BSJ; Cohen MS
    Neoplasia; 2017 Dec; 19(12):1003-1011. PubMed ID: 29121598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer.
    Kumar B; Yadav A; Hideg K; Kuppusamy P; Teknos TN; Kumar P
    PLoS One; 2014; 9(3):e93208. PubMed ID: 24675768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.